Amgen's Q3 results showed flat revenues and a decline in net income due to higher expenses and taxes. However, the company reaffirmed revenue guidance and has an upcoming PDUFA date for Denosumab in oncology on November 18, which could serve as a significant positive catalyst. Despite challenges with Prolia's launch and concerns over EPOGEN sales, the anticipation of regulatory approval may bolster the stock in the short term.

[1]